Centessa Pharmaceuticals plc
CNTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $15 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $15 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $42 | $43 | $33 | $61 |
| G&A Expenses | $12 | $12 | $12 | $14 |
| SG&A Expenses | $12 | $12 | $12 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $54 | $55 | $46 | $75 |
| Operating Income | -$54 | -$55 | -$31 | -$75 |
| % Margin | – | – | -205.2% | – |
| Other Income/Exp. Net | -$1 | $5 | $6 | -$36 |
| Pre-Tax Income | -$55 | -$50 | -$25 | -$110 |
| Tax Expense | $0 | $1 | $1 | $1 |
| Net Income | -$55 | -$50 | -$26 | -$111 |
| % Margin | – | – | -174.2% | – |
| EPS | -0.41 | -0.38 | -0.2 | -0.84 |
| % Growth | -7.9% | -90% | 76.2% | – |
| EPS Diluted | -0.41 | -0.38 | -0.2 | -0.84 |
| Weighted Avg Shares Out | 134 | 134 | 133 | 132 |
| Weighted Avg Shares Out Dil | 134 | 134 | 133 | 132 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $4 | $8 | $5 |
| Interest Expense | $3 | $3 | $3 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$52 | -$46 | -$22 | -$108 |
| % Margin | – | – | -144.3% | – |